BioDrugs

, Volume 15, Issue 4, pp 251–259

Tumour Necrosis Factor-α Blockers in Rheumatoid Arthritis

Review of the Clinical Experience

Authors

  • Corinne Richard-Miceli
    • Clinique de Rhumatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de ParisUniversité René Descartes
    • Centre d’Etude du Polymorphisme HumainHôpital Saint-Louis
    • Clinique de Rhumatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de ParisUniversité René Descartes
Review Article

DOI: 10.2165/00063030-200115040-00005

Cite this article as:
Richard-Miceli, C. & Dougados, M. BioDrugs (2001) 15: 251. doi:10.2165/00063030-200115040-00005

Abstract

Tumour necrosis factor (TNF)-α has been found to play a central role in the pathogenesis of rheumatoid arthritis, leading to development of novel drug therapies that neutralise the deleterious effects of this cytokine. This new concept of immunobiological treatment of rheumatoid arthritis has yielded successful results. Although the 2 currently available TNFα blockers, infliximab and etanercept, differ in structure, mechanism of action and pharmacokinetics, they have provided similar benefits both in clinical improvement and in slowing and even arresting the progression of radiographic damage. This therapeutic response seems to be unequalled by ‘conventional’ treatments in rheumatoid arthritis, and is incontestably a turning point in the therapeutic management of this disease.

Copyright information

© Adis International Limited 2001